Prelude Capital Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Prelude Capital Management’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-49,600	Closed	-$313K	–	1638
2022 Q4	$313K	Buy	+49,600	New	+$275K	0.02%	782

Prelude Capital Management's FSTX Position: Q1 2023 in Review

Prelude Capital Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 60,807 shares — an estimated $384K sold.

Prelude Capital Management first reported a position in FSTX in Q2 2022 and held it in 3 quarters. The position peaked at $384K in Q4 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

Prelude Capital Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Prelude Capital Management sold 60,807 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $384K.
Prelude Capital Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Prelude Capital Management's F-star Therapeutics, Inc. Common Stock position peaked at $384K in Q4 2022.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Prelude Capital Management's 13F filing for Q1 2023, filed 15 May 2023.